Why Novo Nordisk Stock Jumped a Lucky 7.7% Today

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders!Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical trial results for refinements of its original Ozempic and Wegovy drugs. Twice in the past two months, investors have been disappointed by the numbers -- 22.7% average weight loss over 68 weeks for CagriSema, and 20.7% weight loss for a 72-week regimen of semaglutide 7.2 milligram (mg).On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as good as those in the trials cited above, however, the speed at which they were achieved has investors cheering, and Novo Nordisk stock is up 7.7% through 10:50 a.m. Friday morning. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool